Shorter proton radiation courses for non-cancerous brain tumors such as meningioma
Tests shorter-course proton or photon radiation in adults with benign brain tumors.
Key facts
- Who runs it
- Emory University
- Where
- Atlanta, United StatesSee the site
- Trial code
- Registry title
- Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study
- Status
- Recruiting
- People taking part
- 70 people, planned
- Started
- 18 Feb 2020
- Expected to end
- 1 Dec 2031
- Type of study
- Interventional, 2 groups
- Treatments tested
- Hypofractionated Radiation Therapy
- Photon Beam Radiation Therapy
- Proton Beam Radiation Therapy
- Quality-of-Life Assessment
- Questionnaire Administration
- Record updated
- 17 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a non-cancerous tumor inside the skull or on a nerve sheath, such as meningioma, pituitary adenoma or schwannoma. People with WHO grade 2-3 meningioma can also join. Everyone must have been advised to have radiation therapy split into several sessions.
- Age
- 18 Years and older
- Sex
- All sexes
- Disease stage
- Benign tumor inside the skull or of a nerve sheath, found by tissue test or by scans. WHO grade 2-3 meningiomas are also allowed.
- Earlier treatment
- Must have been advised by doctors to have proton or photon radiation therapy given in several sessions. Cannot join after earlier radiation to the same area.
Main reasons for not taking part
- Pregnant women
- Women who could become pregnant and will not use birth control as set by the study
- Earlier radiation therapy that would overlap the area to be treated now
- Unable to have an MRI scan
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Pathologically or radiographically diagnosed benign intracranial or nerve sheath tumor, including meningiomas, pituitary adenomas, schwannomas. World Health Organization (WHO) grade 2-3 meningiomas are also allowed
- Recommended to receive proton or photon fractionated radiation therapy
- Signed informed consent
Who cannot take part
- Prior radiation therapy that would overlap with current target volume
- Pregnant females are excluded. Female of child-bearing potential (FCBP) must have a negative serum or urine pregnancy test prior to starting therapy. FCBP must agree to use adequate contraception (at least one highly effective method and one additional method of birth control at the same time or complete abstinence) prior to study entry, for the duration of study. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately; A female of childbearing potential (FCBP) is a sexually mature woman who: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 12 consecutive months (if age >= 55 years); if the female subject is < 55 years and she has been naturally postmenopausal for >= 1 year her reproductive status has to be verified by additional laboratory (lab) tests (< 20 estradiol OR estradiol < 40 with follicle stimulating hormone [FSH] > 40 in women not on estrogen replacement therapy)
- Inability to undergo magnetic resonance imaging (MRI)
Where in United States
- Emory University Hospital/Winship Cancer InstituteAtlanta, United StatesContact: Bree R. EatonTaking people
About the trial
What the trial wants to find out
This phase II trial studies how well hypofractionated proton or photon radiation therapy works in treating patients with brain tumors. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells. A shorter duration of radiation treatment may avoid some of the delayed side effects of radiation while providing a more convenient treatment and reducing costs.
The 2 groups in the trial
- Cohort I (hypofractionated radiation therapy)Treatment being tested
Patients with benign and radiographically diagnosed intracranial tumors undergo hypofractionated proton or photon radiation therapy daily, Monday-Friday over 17 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity.
Treatment: Hypofractionated Radiation Therapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment, and Questionnaire Administration
- Cohort II (hypofractionated radiation therapy)Treatment being tested
Patients with pathologically confirmed World Health Organization (WHO) grade 2-3 meningiomas undergo hypofractionated proton or photon radiation therapy daily, Monday-Friday over 20 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity.
Treatment: Hypofractionated Radiation Therapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment, and Questionnaire Administration
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- HiPPI: A Phase 2 Trial of Hypofractionated Pencil Beam Scanning Proton Therapy for Benign Intracranial Tumors
- Plain-language title
- Shorter proton radiation courses for non-cancerous brain tumors such as meningiomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 17 February 2026